The Humanistic and Economic Burden of Alzheimer's Disease

Atri A. The Alzheimer’s disease clinical spectrum: diagnosis and management. Med Clin N Am. 2019;103(2):263–93. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–16. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17. Cimler R, Maresova P, Kuhnova J, et al. Predictions of Alzheimer’s disease treatment and care costs in European countries. PLoS ONE. 2019;14(1):e0210958. Clay E, Zhou J, Yi ZM, et al. Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study. J Market Access Health Policy. 2019;7(1):1667195. Jia J, Wei C, Chen S, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement. 2018;14(4):483–91. Zissimopoulos J, Crimmins E, St CP. The value of delaying Alzheimer’s disease onset. Forum Health Econ Policy. 2014;18(1):25–39. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92. Dourado MC, Sousa MF, Santos RL, et al. Quality of life in mild dementia: patterns of change in self and caregiver ratings over time. Braz J Psychiatry. 2016;38(4):294–300. Castro-Monteiro E, Alhayek-Ai M, Diaz-Redondo A, et al. Quality of life of institutionalized older adults by dementia severity. Int Psychogeriatr. 2016;28(1):83–92. Martyr A, Nelis SM, Quinn C, et al. Living well with dementia: a systematic review and correlational meta-analysis of factors associated with quality of life, well-being and life satisfaction in people with dementia. Psychol Med. 2018;48(13):2130–9. Webster L, Groskreutz D, Grinbergs-Saull A, et al. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technol Assess (Winchester, Engl). 2017;21(26):1–192. Roen I, Selbaek G, Kirkevold O, et al. Resource Use and Disease Course in dementia–Nursing Home (REDIC-NH), a longitudinal cohort study; design and patient characteristics at admission to Norwegian nursing homes. BMC Health Serv Res. 2017;17(1):365. Reed C, Barrett A, Lebrec J, et al. How useful is the EQ-5D in assessing the impact of caring for people with Alzheimer’s disease? Health Qual Life Outcomes. 2017;15(1):16. Torisson G, Stavenow L, Minthon L, et al. Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients. Health Qual Life Outcomes. 2016;14:90. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, D.C.: American Psychiatric Association; 1994. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939–44. Gomez-Gallego M, Gomez-Garcia J, Ato-Lozano E. The mediating role of depression in the association between disability and quality of life in Alzheimer’s disease. Aging Ment Health. 2017;21(2):163–72. Barbe C, Jolly D, Morrone I, et al. Factors associated with quality of life in patients with Alzheimer’s disease. BMC Geriatr. 2018;18(1):159. Barbe C, Morrone I, Wolak-Thierry A, et al. Impact of functional alterations on quality of life in patients with Alzheimer’s disease. Aging Ment Health. 2017;21(5):571–6. Beerens HC, de Boer B, Zwakhalen SM, et al. The association between aspects of daily life and quality of life of people with dementia living in long-term care facilities: a momentary assessment study. Int Psychogeriatr. 2016;28(8):1323–31. Millenaar J, Hvidsten L, de Vugt ME, et al. Determinants of quality of life in young onset dementia - results from a European multicenter assessment. Aging Ment Health. 2017;21(1):24–30. Akpınar Söylemez B, Küçükgüçlü Ö, Akyol MA, et al. Quality of life and factors affecting it in patients with Alzheimer’s disease: a cross-sectional study. Health Qual Life Outcomes. 2020;18(1):304. Dourado MCN, Santos RL, Fischer A, et al. Modeling Quality of Life in Alzheimer Disease: the impact of cognitive, functional, and mood variables in self and carers’ perceptions. J Geriatr Psychiatry Neurol. 2020;34:668–74. Lima S, Sevilha S, Pereira MG. Quality of life in early-stage Alzheimer’s disease: the moderator role of family variables and coping strategies from the patients’ perspective. Psychogeriatrics. 2020;20(5):557–67. Schumann C, Alexopoulos P, Perneczky R. Determinants of self- and carer-rated quality of life and caregiver burden in Alzheimer disease. Int J Geriatr Psychiatry. 2019;34(10):1378–85. Smit D, de Lange J, Willemse B, et al. Activity involvement and quality of life of people at different stages of dementia in long term care facilities. Aging Ment Health. 2016;20(1):100–9. Zucchella C, Bartolo M, Bernini S, et al. Quality of life in Alzheimer disease: a comparison of patients’ and caregivers’ points of view. Alzheimer Dis Assoc Disord. 2015;29(1):50–4. Hongisto K, Hallikainen I, Selander T, et al. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer’s disease: 5-year prospective ALSOVA cohort study. Int J Geriatr Psychiatry. 2018;33(1):47–57. Orgeta V, Orrell M, Hounsome B, et al. Self and carer perspectives of quality of life in dementia using the QoL-AD. Int J Geriatr Psychiatry. 2015;30(1):97–104. Sousa MFB, Santos RL, Simoes P, et al. Discrepancies between Alzheimer’s disease patients’ and caregivers’ ratings about patients’ quality of life: a 1-year observation study in Brazil. Alzheimer Dis Assoc Disord. 2018;32(3):240–6. Huang HL, Weng LC, Tsai YH, et al. Predictors of self- and caregiver-rated quality of life for people with dementia living in the community and in nursing homes in northern Taiwan. Int Psychogeriatr. 2015;27(5):825–36. Kimura NRS, Baptista MAT, Santos RL, et al. Caregivers’ perspectives of quality of life of people with young- and late-onset Alzheimer disease. J Geriatr Psychiatry Neurol. 2018;31(2):76–83. Sousa MF, Santos RL, Nogueira ML, et al. Awareness of disease is different for cognitive and functional aspects in mild Alzheimer’s disease: a one-year observation study. J Alzheimers Dis. 2015;43(3):905–13. Stites SD, Karlawish J, Harkins K, et al. Awareness of mild cognitive impairment and mild Alzheimer’s disease dementia diagnoses associated with lower self-ratings of quality of life in older adults. J Gerontol B Psychol Sci Soc Sci. 2017;72(6):974–85. Anderson ND. State of the science on mild cognitive impairment (MCI). CNS Spectr. 2019;24(1):78–87. Song D, Yu DS, Li PW, et al. Correlates of health-related quality of life among Chinese older adults with mild cognitive impairment. Clin Interv Aging. 2019;14:2205–12. Stites SD, Harkins K, Rubright JD, et al. Relationships between cognitive complaints and quality of life in older adults with mild cognitive impairment, mild Alzheimer disease dementia, and normal cognition. Alzheimer Dis Assoc Disord. 2018;32(4):276–83. Roehr S, Luck T, Pabst A, et al. Subjective cognitive decline is longitudinally associated with lower health-related quality of life. Int Psychogeriatr. 2017;29(12):1939–50. Leng M, Yin H, Zhang P, et al. Sleep quality and health-related quality of life in older people with subjective cognitive decline, mild cognitive impairment, and Alzheimer Disease. J Nerv Ment Dis. 2020;208(5):387–96. Trigg R, Jones RW, Knapp M, et al. The relationship between changes in quality of life outcomes and progression of Alzheimer’s disease: results from the dependence in AD in England 2 longitudinal study. Int J Geriatr Psychiatry. 2015;30(4):400–8. Olazaran J, Aguera-Ortiz L, Argimon JM, et al. Costs and quality of life in community-dwelling patients with Alzheimer’s disease in Spain: results from the GERAS II observational study. Int Psychogeriatr. 2017;29(12):2081–93. Hongisto K, Väätäinen S, Martikainen J, et al. Self-rated and caregiver-rated quality of life in Alzheimer disease with a focus on evolving patient ability to respond to questionnaires: 5-year prospective ALSOVA cohort study. Am J Geriatr Psychiatry. 2015;23(12):1280–9. Robinson RL, Rentz DM, Bruemmer V, et al. Observation of patient and caregiver burden associated with early Alzheimer’s disease in the United States: design and baseline findings of the GERAS-US Cohort Study1. J Alzheimers Dis. 2019;72(1):279–92. Kahle-Wrobleski K, Andrews JS, Belger M, et al. Dependence levels as interim clinical milestones along the continuum of Alzheimer’s disease: 18-month results from the GERAS observational study. J Prev Alzheimers Dis. 2017;4(2):72–80. Clemmensen FK, Hoffmann K, Siersma V, et al. The role of physical and cognitive function in performance of activities of daily living in patients with mild-to-moderate Alzheimer’s disease - a cross-sectional study. BMC Geriatr. 2020;20(1):513. Ascher-Svanum H, Chen YF, Hake A, et al. Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes. Clin Ther. 2015;37(6):1195–205. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341–50. Giebel CM, Challis DJ, Montaldi D. A revised interview for deterioration in daily living activities in dementia reveals the relationship between social activities and well-being. Dementia (London). 2016;15(5):1068–81. Sun M, Mainland BJ, Ornstein TJ, et al. The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia. Int J Geriatr Psychiatry. 2018;33(2):e280–5. Votruba KL, Persad C, Giordani B. Patient mood and instrumental activities of daily living in Alzheimer disease: relationship between patient and caregiver reports. J Geriatr Psychiatry Neurol. 2015;28(3):203–9. Roehr S, Riedel-Heller SG, Kaduszkiewicz H, et al. Is function in instrumental activities of daily living a useful feature in predicting Alzheimer’s disease dementia in subjective cognitive decline? Int J Geriatr Psychiatry. 2019;34(1):193–203. Li L, Nguyen KH, Comans T, et al. Utility-based instruments for people with dementia: a systematic review and meta-regression analysis. Value Health. 2018;21(4):471–81. Lacey L, Bobula J, Rudell K, et al. Quality of life and utility measurement in a large clinical trial sample of patients with mild to moderate Alzheimer’s disease: determinants and level of changes observed. Value Health. 2015;18(5):638–45. Cheung YB, Tan HX, Wang VW, et al. Mapping the Alzheimer’s Disease cooperative study-activities of daily living inventory to the health utility index mark III. Qual Life Res. 2019;28(1):131–9. Michalowsky B, Xie F, Kohlmann T, et al. Acceptability and validity of the EQ-5D in patients living with dementia. Value Health. 2020;23(6):760–7. Pusswald G, Moser D, Pflüger M, et al. The impact of depressive symptoms on health-related quality of life in patients with subjective cognitive decline, mild cognitive impairment, and Alzheimer’s disease. Int Psychogeriatr. 2016;28(12):2045–54. El-Hayek YH, Wiley RE, Khoury CP, et al. Tip of the Iceberg: assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis. 2019;70(2):323–41. Pena-Longobardo LM, Rodriguez-Sanchez B, Oliva-Moreno J, et al. How relevant are social costs in economic evaluations? The case of Alzheimer's disease. Eur J Health Econ. 2019. Wimo A, Guerchet M, Ali GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13(1):1–7. Maresova P, Dolejs J, Kuca K. Call for a uniform strategy of collecting Alzheimer’s disease costs: a review and meta-analysis. J Alzheimers Dis. 2018;63(1):227–38. Darba J, Kaskens L, Lacey L. Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in Spain. Eur J Health Econ. 2015;16(8):895–905. Nakanishi M, Igarashi A, Ueda K, et al. Costs and resource use associated with community-dwelling patients with Alzheimer’s Disease in Japan: baseline results from the prospective observational GERAS-J study. J Alzheimers Dis. 2020;74(1):127–38. Reed C, Happich M, Argimon JM, et al. What drives country differences in cost of Alzheimer’s Disease? An explanation from resource use in the GERAS study. J Alzheimers Dis. 2017;57(3):797–812. Henderson C, Knapp M, Nelis SM, et al. Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort study. Alzheimer’s Dementia (New York, N Y). 2019;5:685–96. Bruno G, Mancini M, Bruti G, et al. Costs and resource use associated with Alzheimer’s disease in Italy: results from an observational study. J Prev Alzheimers Dis. 2018;5(1):55–64. Chiatti C, Furneri G, Rimland JM, et al. The economic impact of moderate stage Alzheimer’s disease in Italy: evidence from the UP-TECH randomized trial. Int Psychogeriatr. 2015;27(9):1563–72. Rapp T, Andrieu S, Chartier F, et al. Resource use and cost of Alzheimer’s Disease in France: 18-month results from the GERAS observational study. Value Health. 2018;21(3):295–303. Yan X, Li F, Chen S, et al. Associated factors of total costs of Alzheimer’s disease: a cluster-randomized observational study in China. J Alzheimers Dis. 2019;69(3):795–806. Robinson RL, Rentz DM, Andrews JS, et al. Costs of early stage Alzheimer’s disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J Alzheimers Dis. 2020;75(2):437–50. Darba J, Kaskens L. Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain. ClinicoEcon Outcomes Res CEOR. 2015;7:387–95. Kahle-Wrobleski K, Andrews JS, Belger M, et al. Clinical and economic characteristics of milestones along the continuum of Alzheimer’s disease: transforming functional scores into levels of dependence. J Prev Alzheimers Dis. 2015;2(2):115–20. Michaud TL, High R, Charlton ME, et al. Dependence stage and pharmacoeconomic outcomes in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2017;31(3):209–17. Jones RW, Lebrec J, Kahle-Wrobleski K, et al. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): the impact on costs and caregiver outcomes. Dementia Geriatr Cognitive Disord Extra. 2017;7(1):87–100. Lenox-Smith A, Reed C, Lebrec J, et al. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer’s disease dementia using a model derived from the UK GERAS observational study. BMC Geriatr. 2018;18(1):57. Belger M, Haro JM, Reed C, et al. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer’s disease dementia. Eur J Health Econ. 2019;20(3):343–55. Bruggenjurgen B, Andersohn F, Ezzat N, et al. Medical management, costs, and consequences of Alzheimer’s disease in Germany: an analysis of health claims data. J Med Econ. 2015;18(6):466–73. Chen Y, Wilson L, Kornak J, et al. The costs of dementia subtypes to California Medicare fee-for-service, 2015. Alzheimers Dement. 2019;15(7):899–906. Jones RW, Romeo R, Trigg R, et al. Dependence in Alzheimer’s disease and service use costs, quality of life, and caregiver burden: the DADE study. Alzheimers Dement. 2015;11(3):280–90. Bayen E, Yaffe K, Cleret de Langavant L, et al. The direct health care cost to Medicare of Down syndrome dementia as compared with Alzheimer’s disease among 2015 Californian beneficiaries. Ann Phys Rehabil Med. 2020. https://doi.org/10.1016/j.rehab.2020.07.011. Darbà J, Marsà A. Hospital incidence, mortality and costs of Alzheimer’s disease in Spain: a retrospective multicenter study. Expert Rev Pharmacoecon Outcomes Res. 2020. https://doi.org/10.1080/14737167.2022.2000862. Pyenson B, Sawhney TG, Steffens C, et al. The real-world medicare costs of Alzheimer disease: considerations for policy and care. J Manag Care Spec Pharm. 2019;25(7):800–9. Desai U, Kirson NY, Ye W, et al. Trends in health service use and potentially avoidable hospitalizations before Alzheimer’s disease diagnosis: a matched, retrospective study of US Medicare beneficiaries. Alzheimer’s Dementia (Amsterdam, Netherlands). 2019;11:125–35. Takechi H, Kokuryu A, Kuzuya A, et al. Increase in direct social care costs of Alzheimer’s disease in Japan depending on dementia severity. Geriatr Gerontol Int. 2019;19(10):1023–9. Nair R, Haynes VS, Siadaty M, et al. Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer’s disease in an administrative claims database. BMC Geriatr. 2018;18(1):243. Lenox-Smith A, Reed C, Lebrec J, et al. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study. BMC Geriatr. 2016;16(1):195. Ton TGN, DeLeire T, May SG, et al. The financial burden and health care utilization patterns associated with amnestic mild cognitive impairment. Alzheimers Dement. 2017;13(3):217–24. Takizawa C, Thompson PL, van Walsem A, et al. Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis. 2015;43(4):1271–84. Black CM, Fillit H, Xie L, et al. Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer’s disease. J Alzheimers Dis. 2018;61(1):185–93. Black CM, Lipton RB, Thiel E, et al. Relationship between treatment initiation and healthcare costs in Alzheimer’s disease. J Alzheimers Dis. 2019;68(4):1575–85. Morris S, Patel N, Baio G, et al. Monetary costs of agitation in older adults with Alzheimer’s disease in the UK: prospective cohort study. BMJ Open. 2015;5(3):e007382. Reed C, Belger M, Scott Andrews J, et al. Factors associated with long-term impact on informal caregivers during Alzheimer’s disease dementia progression: 36-month results from GERAS. Int Psychogeriatr. 2020;32(2):267–77. Khandker RK, Ritchie CW, Black CM, et al. Multi-national, cross-sectional survey of healthcare resource utilization in patients with all stages of cognitive impairment, analyzed by disease severity, country, and geographical region. J Alzheimers Dis. 2020;75(4):1141–52. Beydoun MA, Beydoun HA, Gamaldo AA, et al. Nationwide inpatient prevalence, predictors, and outcomes of Alzheimer’s disease among Older Adults in the United States, 2002–2012. J Alzheimers Dis. 2015;48(2):361–75. Keeney T, Belanger E, Jones RN, et al. High-need phenotypes in medicare beneficiaries: drivers of variation in utilization and outcomes. J Am Geriatr Soc. 2019;68:70–7. Yu X, Chen S, Chen X, et al. Clinical management and associated costs for moderate and severe Alzheimer’s disease in urban China: a Delphi panel study. Translational neurodegeneration. 2015;4:15. Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Institutionalization risk and costs associated with agitation in Alzheimer’s disease. Alzheimer’s Dement (New York, N Y). 2019;5:851–61. Lin PJ, Zhong Y, Fillit HM, et al. Medicare expenditures of individuals with Alzheimer’s disease and related dementias or mild cognitive impairment before and after diagnosis. J Am Geriatr Soc. 2016;64(8):1549–57. Albrecht JS, Hanna M, Kim D, et al. Increased health care utilization in dementia subtypes before diagnosis. Alzheimer Dis Assoc Disord. 2018;32(4):326–32. Wimo A, Handels R, Winblad B, et al. Quantifying and describing the natural history and costs of Alzheimer’s disease and effects of hypothetical interventions. J Alzheimers Dis. 2020;75(3):891–902. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484–96. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.